ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Design and baseline findings of the NEODEM prospective cohort on early-onset neurodegenerative dementia.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFunctional prognosis of early-onset neurodegenerative dementia (EOD) remains poorly understood.
methodsThe Neurodegenerative Early-Onset Dementia (NEODEM) study is an ongoing prospective multicenter cohort study investigating factors associated with decline in daily activities in EOD. Detailed information on behavioral and psychological symptoms of dementia (BPSD) is collected as prognostic factor.
resultsBetween May 2020 and May 2023, 162 patients with EOD, including 111 patients with early-onset Alzheimer's disease (AD) and 40 with frontotemporal dementia (FTD) variants, were enrolled in seven tertiary memory clinics in France. The median time from symptom onset to diagnosis was 3 years. By design, Clinical Dementia Rating (CDR) scale score was 0.5 or 1 at inclusion. Baseline level of autonomy was similar in early-onset AD and FTD, but MMSE scores were lower in AD. Baseline BPSD results are presented in the manuscript.
conclusionFour-year longitudinal data, available from 2027, will help clarify the impact of baseline factors on future functional status, institutionalization, morbidity, and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.